Literature DB >> 11830524

Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays.

Yan Dong1, Howard E Ganther, Carleton Stewart, Clement Ip.   

Abstract

Past research indicated that methylseleninic acid (MSA) is an excellent tool for investigating the cancer chemopreventive action of selenium in vitro. The present study was designed to examine the cellular and molecular effects of MSA in the MCF10AT1 and MCF10AT3B premalignant human breast cells. After exposure to MSA, both cell lines exhibited a dose- and time-dependent growth-inhibitory response as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay. Further characterization of cellular and molecular changes was carried out only with the MCF10AT1 cells. Flow cytometry analysis showed that MSA blocked cell cycle progression at the G(0)-G(1) phase. Induction of apoptosis was also observed with the use of either the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) or the annexin V binding method. cDNA microarray analyses with cell cycle- and apoptosis-targeted arrays were then applied to profile the gene expression changes mediating these two cellular events. The analyses were conducted at 6 and 12 h of MSA treatment using synchronized cells. The expression signals of 30 genes were found to be significantly altered by MSA. These genes fall into three categories: cell cycle checkpoint controllers (e.g., cyclins, cdcs, cdks, E2F family proteins, and serine/threonine kinases), apoptosis regulatory genes (e.g., Apo-3, c-jun, and cdk5/cyclin D1), and signaling molecules [e.g., mitogen-activated protein (MAP)/extracellular signal-regulated protein kinase (ERK) and phosphatidylinositol 3'-kinase (PI3k) cascade genes]. The expression changes of 15 genes were selected for verification by Western or semiquantitative reverse transcription-PCR analyses. An agreement rate of 60% (9 of 15) was obtained from these confirmation experiments. On the basis of the above findings, tentative signaling pathways mediating the outcome of selenium-induced cell cycle arrest and apoptosis are proposed. The present study thus demonstrated the feasibility of applying cDNA microarray technology in delineating the mechanisms of the action of selenium and in pinpointing molecular targets as potential biomarkers for evaluating the efficacy of selenium intervention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830524

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Seleno-short-chain chitosan induces apoptosis in human non-small-cell lung cancer A549 cells through ROS-mediated mitochondrial pathway.

Authors:  Yana Zhao; Shaojing Zhang; Pengfei Wang; Shengnan Fu; Di Wu; Anjun Liu
Journal:  Cytotechnology       Date:  2017-04-18       Impact factor: 2.058

2.  Activation of FOXO1 is critical for the anticancer effect of methylseleninic acid in prostate cancer cells.

Authors:  Haitao Zhang; Jian Fang; Dian Yao; Yue Wu; Clement Ip; Yan Dong
Journal:  Prostate       Date:  2010-09-01       Impact factor: 4.104

3.  The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D.

Authors:  Michael Hagemann-Jensen; Franziska Uhlenbrock; Stephanie Kehlet; Lars Andresen; Charlotte Gabel-Jensen; Lars Ellgaard; Bente Gammelgaard; Søren Skov
Journal:  J Biol Chem       Date:  2014-09-25       Impact factor: 5.157

4.  Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.

Authors:  Rami G Azrak; Shousong Cao; Lakshmi Pendyala; Farukh A Durrani; Marwan Fakih; Gerald F Combs; Joshua Prey; Patrick F Smith; Youcef M Rustum
Journal:  Biochem Pharmacol       Date:  2006-12-22       Impact factor: 5.858

5.  Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.

Authors:  Jae Yeon Chun; Yan Hu; Elaine Pinder; Jianguo Wu; Fengzhi Li; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

6.  Porcine serum can be biofortified with selenium to inhibit proliferation of three types of human cancer cells.

Authors:  Lv-Hui Sun; Jun-Gang Li; Hua Zhao; Jing Shi; Jia-Qiang Huang; Kang-Ning Wang; Xin-Jie Xia; Li Li; Xin Gen Lei
Journal:  J Nutr       Date:  2013-05-15       Impact factor: 4.798

7.  Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model.

Authors:  Christopher M Lyon; Donna M Klinge; Kieu C Do; Marcie J Grimes; Cindy L Thomas; Leah A Damiani; Thomas H March; Christine A Stidley; Steven A Belinsky
Journal:  Carcinogenesis       Date:  2009-12       Impact factor: 4.944

8.  Chemopreventive doses of methylselenocysteine alter circadian rhythm in rat mammary tissue.

Authors:  Xun Zhang; Helmut Zarbl
Journal:  Cancer Prev Res (Phila)       Date:  2008-07

9.  Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells.

Authors:  Hongjuan Zhao; Michael L Whitfield; Tong Xu; David Botstein; James D Brooks
Journal:  Mol Biol Cell       Date:  2003-11-14       Impact factor: 4.138

10.  Selenium in the prevention of human cancers.

Authors:  Mikael Björnstedt; Aristi P Fernandes
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.